1. Will other drugmakers end up with deals like Endo’s $10M opioid settlement? — AstraZeneca Imfinzi combo fails advanced lung cancer study — FDA says they were “lucky” with Novartis data manipulation controversy — See more on our front page news

    TRY TWO WEEKS OF OUR EMAIL NEWS HEADLINES FOR FREE
    Dismiss Notice
  2. What happened a year ago this week in biopharma? Regeneron’s Eylea approval, Novartis’ new ethics czar, Vertex’s Kalydeco, and Opidvo’s SCLC approval click to review and read a current update of the big stories from one year ago
    Dismiss Notice

Love, Chimp

Discussion in 'Zogenix' started by Anonymous, Feb 20, 2015 at 3:44 PM.

Tags: Add Tags
  1. Anonymous

    Anonymous Guest

    You have to think RH can't wait for this board to disappear quickly enough. That guy should have a BlackBox warning for inept leadership skills and gets a solid F for knowing his market. Fucking Zogenix.

    P
    A
    T
    H
    E
    T
    I
    C
     
  2. Anonymous

    Anonymous Guest

    But I will give him an academy award for best portray of human who gives a damn about others! He had us all fooled.
     
  3. Anonymous

    Anonymous Guest

    I believed in the manager that hired me because he believed in R and his vision. I in turn FELT it. You didn't stay here/last this long if you didn't.

    I know it's just business but it is still raw and it hurts. After all that has happened- all we have been through-

    An article I read today said that they would have enough people left to cover the Dravet product. I wonder -have they retained some reps? Or are the San Diego people going to order helicopters and pick up bags...
     
  4. Anonymous

    Anonymous Guest

    I would say that nobody will be left except home office people and they will hire people to cover the Dravet accounts if and when that ever happens. I have no faith in the future here at all at this point.
     
  5. Anonymous

    Anonymous Guest

    Dravet? It's fucking fenfluramine. Do you know epilepsy at all? Everything is generic including the most effective broad spectrum product ever marketing - Keppra.

    Now...if they keep McCarville and Symansky - they got a shot.
     
  6. Anonymous

    Anonymous Guest

    don't make me laugh. first the drug is fenfluramine. POS. and if you ever sold in Epilepsy you would know three critical things...
    1. Keppra (leviteracetam) is now generic. It's broad spectrum and shown to be the most effective product in therapy.
    2. Everything is generic.
    3. Nearly all of these afflicted with Dravet, at some point become wards of the state. Guess what? The states are broke. They don't pay for Brand products in a highly enriched generic marketplace.

    All in all... nice work again San Diego.
     
  7. Anonymous

    Anonymous Guest

    What? There is one light bulb that works here in the former field sales department? Good for you buddy. Future? Baaahhhhhhahahahahahah
     
  8. Anonymous

    Anonymous Guest

    What are you talking about? Seriously?... You've been here what, a little over a year. The writing was on the wall from the start that this was a short-term job. you've had 10-12 months to look for something else. Jesus, anyone with a brain knew that Zohydro was a gamble from its inception with the way states view narcotics today. The stock options were the biggest clue this was high risk. Then they hired many managers and reps with zero pain experience. How much more obvious did you need it to be? I told you then on Cafepharma and I'll tell you again, it was always a short-term double dipping job. Nothing more, nothing less.
     
  9. Anonymous

    Anonymous Guest

    Theres a lot to what you say in that there was a high degree of risk. I came here 5 years ago knowing the risks and knew Zohydro was going to be the biggest risk of all. I think you are wrong that it was always a short-term gig. In hindsight it turned out to be that but the management team believed they would either get a massive buyout or zohydro would take Zogenix to the next level. Clearly neither happened but I know that they beleived it could be done.
     
  10. Anonymous

    Anonymous Guest

    And you thought that Zogenix would go to the next level too tree hugger.
    Look at RH. Fat greedy pig. Know nothing that surrounded himself with more know nothings. Why do I say that? Watch where they all end up. Zero talent. Of course they wanted the massive buyout. Now? Even if Pernix gets the funding - which I don't think they will...$100M barely covers the loans these idiots signed up for.

    RH ruined careers. Biggest fraud ever to lead the show.
     
  11. Anonymous

    Anonymous Guest

    Hey jackass, you quote this no pain experience reps stuff in multiple threads as a reason why Zohydro failed. In fact, many reps with no pain experience at all were ranked highest while many reps bragging about great relationships and experience sucked this place dry with no sales at all. You're an idiot with no life. I'm sure you were fired for not selling anything, which is why you keep coming back here to spew your garbage.
     
  12. Anonymous

    Anonymous Guest

    RH ruined careers? Really? No question that it didnt work out the way anyone thought it would but this seems a little extreme.
     
  13. Anonymous

    Anonymous Guest




    Purdue has plenty of pain experience, deep pockets and they are struggling with their new product as well. The opioid market is a tough one and most especially with the abuse epidemic that is happening in our country. Insurance companies dictate success or failure if a new drug and Purdue smeared the insurance companies years ago with the abuse of Oxy. They want nothing to do with another opiated that might "take off" and succeed . ADF is a joke. Those who want will figure it out and abuse it. The ADF is a way for pharm companies to act like they are going the right thing for the big picture but it's a political football and unt it gets legislated into use by the governing bodies, the insurance companies wil never let it happen. So you can guess that is what Purdue is doing, padding the pockets of the FDA and lobbying like a mofo! No shame in their game !
     
  14. Anonymous

    Anonymous Guest

    Wow!!! Look again folks, and this applies to you too, because your ignorance is worn on your face proudly; thus, it is high-time that you to gain a reality check of sorts. Look at the very dedicated “pay to play” docs in New York and New Jersey, and their contribution to overall Zohydro sales. Do you really believe that ANY Zogenix sales reps within these states owned special skills to motivate Zohydro prescriptions (of size)? Think again, the pain specialists in New York and New Jersey (that were willing, and who continue to prostitute themselves for their individual enrichment), each pull down 60K a quarter (approximately) to push a select few products for a select group of pharma companies. Some of these docs have not held their medical licenses long enough to be considered an authority on any disease state. Sorry, I recognize that you believe the BS that you attempt to sell, but the true reality is much different than your idiotic narrative.

     
  15. Anonymous

    Anonymous Guest

    Fortunately, I navigate the world with a broader narrative than you appear to own. Nevertheless, good luck to you and your apparent micro-sized cognitive construct.

    However, I will be more specific in context of the price of Zogenix shares. I have calculated that the share price at these levels equates to successful approval associated to both of your products and I have allowed for a reasonable approval “time-frame” within those calculations. Thus, who will be first to unload, and that is what I am waiting to see; thus, I am way ahead of you.